Showing all 3 results

  • Placeholder
    In Stock

    Clindipine Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, Light-Shielded Cardiovascular Tablet, packed exclusively in highly secure, opaque Alu-Alu blister strips to ensure the absolute chemical stability of the highly photosensitive active ingredient.

    Active IngredientStrengthPrimary Clinical Function
    Cilnidipine USP/Ph.Eur.5 mgThe Geriatric & Titration Anchor: The definitive starting dose utilized for elderly patients or those with mild essential hypertension to prevent sudden hypotensive episodes.
    Cilnidipine USP/Ph.Eur.10 mgThe Global Maintenance Standard: The standardized daily therapeutic payload utilized for the vast majority of adult patients requiring chronic 24-hour blood pressure control.
    Cilnidipine USP/Ph.Eur.20 mgThe Severe Refractory Macrodose: Utilized strictly for severe, uncontrolled hypertension where the 10mg dose has failed to achieve target blood pressure metrics.
    ExcipientsMicrocrystalline Cellulose / Lactose Monohydrate / Croscarmellose Sodium / Hypromellose / Magnesium Stearate / Opaque Polymeric Film (Titanium Dioxide base)Diluent / Densifier / Superdisintegrant / Binder / Lubricant / Protective Light Shield (Engineered specifically utilizing a dense, titanium dioxide-heavy film coat. Cilnidipine is intensely sensitive to UV and visible light; this opaque coating guarantees 100% of the active molecule survives to reach the patient’s systemic circulation)

    *Pack Sizes: 10×10 Opaque Alu-Alu Blisters (Optimized specifically for strict 30-day chronic cardiology dispensing regimens).

  • Placeholder
    In Stock

    Erlotinib Tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the targeted antineoplastic API.

    Active IngredientStrengthPrimary Clinical Function
    Erlotinib (as Hydrochloride) USP/Ph.Eur.100 mgThe Pancreatic Oncology Standard: The definitive daily maintenance dose utilized globally in combination with Gemcitabine for advanced, unresectable, or metastatic pancreatic cancer.
    Erlotinib (as Hydrochloride) USP/Ph.Eur.150 mgThe Thoracic Oncology Standard: Massive therapeutic payload utilized as a first-line, maintenance, or second-line daily monotherapy for EGFR-mutated Non-Small Cell Lung Cancer.
    ExcipientsLactose Monohydrate / Microcrystalline Cellulose / Sodium Starch Glycolate / Sodium Lauryl Sulfate / Magnesium Stearate / Premium Polymeric FilmDiluent / Binder / Superdisintegrant / Surfactant / Heavy Film-Coating (Engineered specifically to maximize dissolution of this highly insoluble compound while locking the potent cytotoxic API safely inside the tablet, completely preventing handler exposure to carcinogenic dust)

    *Pack Sizes: 3×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic oncology dispensing regimens).

  • Placeholder
    In Stock

    Gefitinib tablets

    Free

    Product Composition & Strength

    We supply this product as a Precision-Blended, High-Density Film-Coated Tablet, packed exclusively in highly secure, moisture-resistant Alu-Alu blister strips or heavy-gauge HDPE bottles to ensure the absolute chemical stability of the targeted antineoplastic agent.

    Active IngredientStrengthPrimary Clinical Function
    Gefitinib USP/Ph.Eur.250 mgGlobal Adult Oncology Standard: The definitive, highly precise daily maintenance dose required to maintain constant, paralyzing pressure on the mutated EGFR protein to keep the lung cancer in deep molecular remission.
    ExcipientsLactose Monohydrate / Microcrystalline Cellulose / Croscarmellose Sodium / Sodium Lauryl Sulfate / Magnesium Stearate / Premium Polymeric FilmDiluent / Binder / Superdisintegrant / Surfactant / Heavy Film-Coating (Engineered specifically to maximize the dissolution of this poorly soluble compound while locking the cytotoxic API safely inside the tablet, completely preventing handler and pharmacist exposure to the carcinogenic dust)

    *Pack Sizes: 10×10 Alu-Alu Blisters or Bottles of 30 (Optimized specifically for strict 30-day chronic oncology dispensing regimens).